Pieris Pharmaceuticals, Inc. (PIRS) News
Filter PIRS News Items
PIRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PIRS News From Around the Web
Below are the latest news stories about PIERIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PIRS as an investment opportunity.
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning! |
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhyPieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning! |
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisUnpacking the Risks and Rewards of Investing in Pieris Pharmaceuticals |
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowPieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificPieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. |
Pieris lays off most staff after AstraZeneca pulls out of partnershipPieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale. |
Pieris (PIRS) Pursues Strategic Alternatives, Stock RisesPieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep. |
Why Pieris Pharmaceuticals Shares Shooting Higher Today?Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled respiratory franchise, including AstraZeneca Plc's (NASDAQ: AZN) discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the company of its decision to terminate the parties' R&D collaboration agreement, hand back elarekibep, and discontinue the remaining discove |